Invion

Invion Intangible Assets

The Intangible Assets of Invion (IVX.AX) as of Oct 28, 2026 is 13.23 M AUD. In the previous year, Intangible Assets was 11.39 M AUD — a change of 16.12% (higher).

Intangible Assets

13.23 MAUD

YoY

16.12%

Last updated:

Intangible Assets of Invion is 2023 13.23 M AUD. Intangible Assets of Invion was 2022 11.39 M AUD. It decreases by 16.12% higher compared to the previous year.

The Invion Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2016
10.76 M AUD
Jan 1, 2017
4.80 M AUD
Jan 1, 2018
7.29 M AUD
Jan 1, 2019
5.12 M AUD
Jan 1, 2020
4.84 M AUD
Jan 1, 2021
4.57 M AUD
Jan 1, 2022
11.39 M AUD
Jan 1, 2023
13.23 M AUD
The Invion Intangible Assets history
YEARIntangible AssetsYoY
13.23 MAUD+16.12%
11.39 MAUD+149.58%
4.57 MAUD-5.68%
4.84 MAUD-5.38%
5.12 MAUD-29.82%
7.29 MAUD+51.76%
4.80 MAUD-55.35%
10.76 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Intangible Assets of Invion is 13.23 M AUD in 2023.

Intangible Assets of Invion changed from 11.39 M AUD to 13.23 M AUD, representing a 16.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Invion since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Invion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Invion

All Key Metrics — Invion